NANEXA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.74 SEK | 0.00% |
|
+19.35% | -39.84% |
| May. 03 | Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 71.3M 6.57M | Sales 2025 * | 69.5M 6.4M | Capitalization | 100M 9.25M |
|---|---|---|---|---|---|
| Net income 2024 * | 16M 1.47M | Net income 2025 * | -4M -368K | EV / Sales 2024 * | 0.49 x |
| Net cash position 2024 * | 65.5M 6.03M | Net cash position 2025 * | 82M 7.55M | EV / Sales 2025 * | 0.26 x |
| P/E ratio 2024 * |
18.5
x | P/E ratio 2025 * |
3.36
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nanexa AB
More press releases
| 1 week | +19.35% | ||
| Current month | +5.71% | ||
| 1 month | -5.37% | ||
| 3 months | -37.82% | ||
| 6 months | -1.60% | ||
| Current year | -39.84% |
1 week
0.64
0.78
1 month
0.600.83
Current year
0.601.45
1 year
0.603.94
3 years
0.6010.50
5 years
0.6015.40
10 years
0.6016.09
| Managers | Title | Age | Since |
|---|---|---|---|
Mårten Rooth
FOU | Founder | 47 | 06-12-31 |
Anders Johansson
FOU | Founder | 48 | 06-12-31 |
David Westberg
CEO | Chief Executive Officer | 64 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 20-06-01 | |
| Director/Board Member | 69 | 22-12-31 | |
| Corporate Officer/Principal | 62 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 0.74 | 0.00% | 846,534 |
| 24-05-06 | 0.74 | +7.56% | 675,147 |
| 24-05-03 | 0.688 | -0.86% | 191,729 |
| 24-05-02 | 0.694 | -0.86% | 75,857 |
| 24-04-30 | 0.7 | +12.90% | 261,317 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 11:29 am EDT
More quotes
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
Calendar
2024-05-14
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.84% | 9.29M | |
| -8.03% | 205M |
- Stock Market
- Equities
- NANEXA Stock